Company insider dossier

VistaGen Therapeutics Inc insider intelligence

VTGN filings assessed for conviction, transaction quality, insider breadth, clustering, freshness, and price confirmation.

Terminal chart Weekly report Factor intelligence Healthcare Biotechnology Data API
75/100

Conviction accumulation

48/100 confidence
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
Latest evidence
29 Jul 2026

Investment committee read

Conviction accumulation

Priced common-share acquisitions carry more weighted evidence than disposals after freshness, role, size, and duplicate controls.

Research constructive setups

Evidence in favour

  • Participation spans 5 named insiders rather than one filing source.

Decision risks

  • The latest qualifying filing is more than 30 days old.
Conviction75Conviction accumulation
Confidence48Developing
Named insiders5participating in the tape
Controlled events2directional common-share events
Acquisition value$16.4Knormalized amount
Disposal value$0normalized amount

Price confirmation map

Weekly price with common-share events

Acquisitions and disposals are aligned to the nearest completed weekly bar.

4.903.732.561.390.23 Acquisition · 30 Jun 2026 · $7.1KAcquisition · 30 Jun 2026 · $7.1KAcquisition · 30 Jun 2026 · $2.2K
Mar 2025Sep 2026
Weekly closeCommon-share acquisitionCommon-share disposal

Market confirmation

Price and trend context

Latest close
0.237 USD
One-week move
-2.4%
Four-week move
-11.4%
Fair-value gap
-91.4%
Trend signal
Inactive
Relative strength
-85.2

Directional balance

Controlled event mix

100.0%acquisition
Acquisition events
2
Disposal events
0
Net value
$16.4K

Cadence

Twelve-week filing pressure

Volume shows attention. Controlled events determine direction.

329 Jun
006 Jul
013 Jul
020 Jul
127 Jul
003 Aug
010 Aug
017 Aug
024 Aug
031 Aug
007 Sep
014 Sep

Named participants

Insider conviction by person

ADLER, REID G.Chief Legal Officer721 events
SINGH, SHAWNDirector, President and CEO721 events
TRESSLER, NICK B.Chief Financial Officer721 events
ANGELOV, ANGEL SChief Medical Officer500 events
WILLIAMSON, DOUGLAS JDirector500 events

Evidence quality

Security and transaction context

Common equity3
Equity compensation0
Options and derivatives2
Other securities0

Role architecture

Who is participating

Other executive2
CEO and chair1
Director1
Finance leadership1

Transaction evidence

Auditable VTGN filing ledger

Showing 1 to 5 of 5.

WILLIAMSON, DOUGLAS JDirector
AcquisitionOptions and derivatives
40826 sharesStock Options (Right to Buy)
Not reportedContext evidence
ADLER, REID G.Chief Legal Officer
AcquisitionCommon equity
36818 sharesCommon Stock
$7.1KDirectional evidence
SINGH, SHAWNDirector, President and CEO
AcquisitionCommon equity
36818 sharesCommon Stock
$7.1KDirectional evidence
TRESSLER, NICK B.Chief Financial Officer
AcquisitionCommon equity
11712 sharesCommon Stock
$2.2KDirectional evidence
ANGELOV, ANGEL SChief Medical Officer
AcquisitionOptions and derivatives
150000 sharesStock Option (Right to Buy)
Not reportedContext evidence

Reading the dossier

Direction and confidence are separate

Conviction

The 0 to 100 score classifies deduplicated priced common-share evidence. Fifty is balanced or non-directional.

Confidence

Confidence rises with controlled event depth, named-insider breadth, fresh evidence, normalized values, and a longer observation span.

Disposals

Selling is not treated as the mirror image of buying. It carries less directional weight because taxes, diversification, compensation, and planned transactions can all create sales.

Price confirmation

The market chart tests whether the filing thesis is being confirmed or rejected by price, fair-value position, relative strength, and the current trend state.

Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.

Evidence context